By proceeding, you agree to our Terms of Use and Privacy Policy.
Join us at the Fluid & Imaging Biomarkers in Neuroscience Summit, the premier industry forum bringing together translational experts, neuroscience drug sponsors, and biomarker technology developers. This groundbreaking event aims to revolutionize the assessment of Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) through the development and integration of validated, cost-effective, non-invasive, and reliable fluid and imaging biomarkers.At the summit, you'll gain access to cutting-edge insights and the latest advancements in biomarker technologies. This unique gathering of experts will address the current translational bottleneck that hampers the success of drug candidates in neurodegenerative and neuro-immunological diseases. By evaluating the most recent biomarker research across AD, PD, MS, and ALS, the summit offers a highly focused platform for meaningful discussions and collaborations.Engage with renowned translational experts and biomarker specialists from leading industry players such as Biogen, Eli Lilly, and Janssen. Through forward-thinking conversations and knowledge-sharing, we aim to drive significant advancements in biomarker assessments for disease-modifying therapeutics targeting neurodegenerative and neuroinflammatory conditions.Don't miss this unparalleled opportunity to be at the forefront of transformative research and development in the field of neuroscience. Join us at the Fluid & Imaging Biomarkers in Neuroscience Summit and contribute to the future of early and accurate assessment of AD, PD, ALS, and MS, ultimately advancing the discovery and development of effective treatments for these debilitating conditions.
Deep dive into the latest developments and advancements in Neuroscience.
Explore the integration of critical fluid and imaging biomarkers to advance neurodegenerative and neuro-immunological drug candidates through clinical trials.
Engage in insightful sessions and discussions to advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.
Hear from industry experts who are shaping the field of fluid imaging biomarkers. Be inspired by advancements and their potential impact on neurology and patient care.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health.
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and re
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.